• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Culmination Bio and Merck Announce R&D Collaboration in Autoimmune Disease Research

by Syed Hamza Sohail 01/25/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • Culmination Bio, a data and technology company combining clinical and biospecimen data, announced an R&D collaboration with Merck, known as MSD, outside the United States and Canada, initially in the area of autoimmune disease.
  • Under the terms of the master agreement, Merck will have access to both clinical (Electronic Health Records, labs, medications) and paired biospecimen (tissue and blood) data from several cohorts of various sizes and qualifications. This project-based collaboration leverages Culmination’s unique ability to build both retrospective and prospective deidentified multi-modal datasets in a disease-defined fashion.

Advancing Pharmaceutical Research Through Extensive Patient Data and Strategic Partnerships


Culmination Bio, a spinoff from Intermountain Health, possesses exclusive rights to a comprehensive collection of de-identified patient electronic health records and biospecimen data spanning over 40 years. With a continuously growing repository of over five million samples, the platform significantly accelerates patient recruitment for pharmaceutical research, aiding companies in rapid research queries. 

Partnering with Intermountain Health facilitates the swift recruitment of potential clinical trial participants. Additionally, the platform enables researchers to conduct quick queries across various data types, supporting groundbreaking research from population-wide genetic studies to drug discovery. In November 2023, Culmination Bio secured investment from Merck Global Health Innovation Fund and Amgen Ventures, allowing further development of its database and expansion in collaboration with pharmaceutical partners.

“Our collaboration with Merck represents a significant milestone in our mission to accelerate healthcare research,” said Lincoln Nadauld, MD, Ph.D., president and CEO of Culmination Bio, “This agreement exemplifies the need for rapid access to high-quality longitudinal patient data spanning decades to inform clinical research.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |